Loading...
•
Dec 31, 2024
Celsion Q4 2024 Earnings Report
Reported financial results for the year ended December 31, 2024, and highlighted recent business updates, including progress in advancing the IMNN-001 development program.
Key Takeaways
IMUNON reported a net loss for 2024 of $18.6 million, or $1.62 per share, compared with a net loss for 2023 of $19.5 million, or $2.16 per share. The company ended 2024 with $5.9 million in cash and cash equivalents.
IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer.
Patient enrollment in Phase 3 pivotal trial of IMNN-001 is scheduled to begin in Q1 2025.
New translational data from OVATION 2 Study reinforce dose-dependent mechanism with IMNN-001 100mg/m2 dose.
Phase 1 proof-of-concept clinical trial of IMNN-101 demonstrate persistent immunogenicity in trial participants.
Forward Guidance
IMUNON believes it has sufficient capital resources to fund its operations into late second quarter of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...